On May 20, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) soared 10.26%, the company announced its first quarter earnings results earlier this month. The company posted net loss of $3.2 million, or $0.05 per basic and diluted share, compared to a net loss of $5.0 million, or $0.10 per basic and diluted share for the quarter ended March 31, 2013. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is 5.00%. On last trading day company shares ended up $1.26. Analysts mean target price for the company is $5.69. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is 2.57%.
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel in New York City. Inovio Presentation Monday, June 2, 2014 8:00 AM ET Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares fell -6.70% in last trading session and ended the day on $2.09 . Its return on assets is -71.90%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly performance is -27.93%.
salesforce.com, inc. (NYSE:CRM) the biggest maker of customer-management software, forecast second-quarter sales that exceeded analysts’ predictions as the company’s Web-based products continue to lure new users. Revenue in the quarter ending in July will be about $1.29 billion, the San Francisco-based company said yesterday in a statement. That topped the $1.27 billion average analyst projection, according to data compiled by Bloomberg. Profit excluding some costs will be 11 cents to 12 cents a share, compared with the 12-cent average estimate. salesforce.com, inc. (NYSE:CRM) shares moved down -5.10% in last trading session and was closed at $50.19, while trading in range of $49.62 – $53.00. salesforce.com, inc. (NYSE:CRM) year to date (YTD) performance is -9.06%.
Zogenix, Inc. (NASDAQ:ZGNX) a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced the closing of its previously announced sale of its SUMAVEL(R) DosePro(R) Needle-free Delivery System (sumatriptan injection) product line to Endo International plc (ENDP) for $85 million in cash and milestone payments of up to $20 million. Zogenix, Inc. (NASDAQ:ZGNX) ended the last trading day at $1.94. Company weekly volatility is calculated as 6.27% and price to cash ratio as 5.34. Zogenix, Inc. (NASDAQ:ZGNX) showed a negative weekly performance of -11.82%.
Dendreon Corporation (NASDAQ:DNDN) announced that it presented data from the ProACT and IMPACT studies on Provenge at the annual meeting of the American Urological Association (AUA.V). Dendreon’s shares gained around 8% following the announcement.Dendreon Corporation (NASDAQ:DNDN) weekly performance is 0.93%. On last trading day company shares ended up $2.18. Analysts mean target price for the company is $2.41. Dendreon Corporation (NASDAQ:DNDN) distance from 50-day simple moving average (SMA50) is -18.25%.